- * Patients suffering from constitutional von Willebrand disease for whom Desmopressin treatment is deemed ineffective or contraindicated
- * Patients suffering from von Willebrand disease and being treated or having been treated with Voncento® for the treatment of surgical and non-surgical bleeding episodes, the prophylaxis of surgical and non-surgical bleedings
- * Patients with no history or suspicion of inhibitors (judged on previous efficacy)
Von Willebrand Disease
Registry of Patients With Von WilLEbrand Disease Treated With Voncento®
NCT04657887 | PHASE 1 | OBSERVATIONAL
Description of the long-term evolution of patients with von Willebrand disease and treated with Voncento® and of the hemostatic efficacy in the prevention and the treatment of non-surgical bleeding episodes and prevention of surgical bleeding during 2 years after patient inclusion.
Trial Information
If interested, contact clinicaltrials@cslbehring.com for more information
CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy
CHU Besanon
Besançon,France
CHU Bordeaux
Bordeaux,France
CHU Morvan Brest
Brest,France
CHU Lyon
Bron,France
CHU Caen
Caen,France
Hpital Simone Veil
Eaubonne,France
Hpital Mignot
Le Chesnay,France
Hpital Bictre
Le Kremlin-Bicêtre,France
Hpital SaintEloi
Montpellier,France
CHRU Nancy
Nancy,France
CHU Nantes
Nantes,France
CHU Lariboisire
Paris,France
Hpital Cochin
Paris,France
Hpital Necker
Paris,France
CHU Rennes
Rennes,France
CHU Rouen
Rouen,France
CHU Strasbourg
Strasbourg,France
Study Eligibility Criteria
Additional Studies
Additional studies can be found at ClinicalTrials.gov